Compass Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CMPX research report →
Range $6 – $9
Price Chart
About the company
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions.
- CEO
- Thomas J. Schuetz
- IPO
- 2021
- Employees
- 39
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on CMPX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $425.91M
- P/E
- -5.70
- Fwd P/E
- 9.34
- PEG
- -0.65
- P/S
- 0.00
- P/B
- 2.66
- EV/EBITDA
- -5.51
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -38.71%
- ROIC
- -46.15%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-1,472,000-273.2%
- Op Income
- $-72,839,000
- Net Income
- $-66,489,000-34.7%
- EPS
- $-0.42-16.7%
- OCF Growth
- -9.6%
- FCF Growth
- -9.5%
- 52W High
- $6.88
- 52W Low
- $1.61
- 50D MA
- $2.12
- 200D MA
- $4.09
- Beta
- 0.82
- RSI (14)
- 60
- Avg Volume
- 3.52M
No earnings-call transcripts are available for CMPX yet.
- Free Float
- 68.1%
- Shares Outstanding
- 180.09M
- Float Shares
- 122.69M
of shares held by institutions
173 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 8.05M | ▲ 985.58K |
| California State Teachers Retirement System | 112.32K | ▲ 104.26K |
| Optimize Financial Inc | 80.44K | ▲ 80.44K |
| Janus Henderson Group PLC | 55.60K | ▲ 55.60K |
| Two Sigma Advisers, LP | 15.20K | ▲ 15.20K |
| Rovin Capital/Adv | 13.49K | 0 |
| Cwm, LLC | 4.32K | ▲ 1.26K |
| Cibc Private Wealth Group, LLC | 38 | ▲ 38 |
| Sunbelt Securities, Inc. | 8 | 0 |
Held by 146 ETFs
Biggest fund positions in CMPX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 29, 26 | Lerner Neil | buy | 15,000 |
| Apr 29, 26 | Anderman Jonathan | buy | 25,000 |
| Apr 29, 26 | Anderman Jonathan | other | 25,000 |
| Apr 29, 26 | Lerner Neil | other | 15,000 |
| Feb 8, 26 | Schuetz Thomas J. | other | 36,687 |
| Jan 9, 26 | Schuetz Thomas J. | other | 46,777 |
| Jan 2, 26 | Shin Barry | other | 670,000 |
| Jan 2, 26 | Shin Barry | other | 125,000 |
| Jan 2, 26 | Sirard Cynthia | other | 1,000,000 |
| Jan 2, 26 | Schuetz Thomas J. | other | 250,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CMPX coverage
Recent articles, reports, and earnings notes.
No research on CMPX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CMPX report →Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update
globenewswire.com · Aug 6
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
globenewswire.com · Jul 17
Compass Therapeutics: A 50% Price Cut Hiding A Regulatory Mispricing Opportunity
seekingalpha.com · Jul 15
Compass Therapeutics, Inc. (CMPX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
seekingalpha.com · Jun 9
Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win
marketbeat.com · Jun 8
Compass Therapeutics to Participate in Upcoming June Investor Events
globenewswire.com · May 28
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
globenewswire.com · May 21
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
gurufocus.com · May 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.